$BMRAOct 16, 2026, 8:19 AM ETAI processed
BMRA Q1 FY2027: inFoods Medicare claims paid at $300; revenue $1.3M, loss $1.2M, cash $2.7M
AI Summary
Biomerica (NASDAQ: BMRA) reported Q1 FY2027: net sales ~$1.3M, gross profit ~$103k (8% margin), operating and net loss of approximately $1.2M, and cash of ~$2.7M after a $2.23M private placement. Commercially, inFoods® IBS is gaining Medicare traction — 100% of initial valid Medicare claims processed as of Oct 15 were paid at the full CMS rate of $300 and Medicare-related test orders rose 120% in September vs August — and the company engaged B. Riley to evaluate strategic opportunities while advancing CDM work with potential initial fees >$1.75M.
Positives
- 100% of initial valid Medicare claims for inFoods IBS processed as of Oct 15 were paid at full CMS rate of $300
- Medicare-related inFoods test orders rose 120% in September vs August, with growing physician repeat orders
- Cash more than doubled to ~$2.7M after an August private placement that raised ~$2.23M
Negatives
- Gross margin plunged to ~8% from 31% year-ago quarter
- Q1 operating and net loss of approximately $1.2M
- Net cash used in operations was ~$802k in the quarter